Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Phathom Pharmaceuticals, Inc. - Common Stock
(NQ:
PHAT
)
7.130
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Phathom Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
October 08, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
September 29, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
September 16, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
Phathom Pharmaceuticals (PHAT) Falls After Cutting 2026 Revenue Guidance Despite Q2 Beat
↗
July 30, 2026
Via
Chartmill
Phathom Pharmaceuticals (NASDAQ:PHAT) Smashes Q1 Expectations, Nears Profitability Milestone
↗
April 30, 2026
Via
Chartmill
Phathom Pharmaceuticals (NASDAQ:PHAT) Q4 2025 Earnings: Revenue Beat and Narrowed Losses Signal Path to Profitability
↗
February 26, 2026
Via
Chartmill
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
September 01, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
August 03, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Phathom Pharmaceuticals Q2 Earnings Call Highlights
↗
July 30, 2026
Phathom Pharmaceuticals (NASDAQ:PHAT) reported second-quarter 2026 revenue growth of 88% year over year and said it achieved positive operating profit excluding stock-based compensation for the first...
Via
MarketBeat
Topics
Earnings
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
July 30, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
July 20, 2026
Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
June 23, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
May 22, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
May 20, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
May 01, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom (PHAT) Q1 2026 Earnings Transcript
↗
April 30, 2026
Phathom (PHAT) Q1 2026 Earnings Transcript
Via
The Motley Fool
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
April 30, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
April 20, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
April 06, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom (PHAT) Q4 2025 Earnings Call Transcript
↗
February 27, 2026
Phathom (PHAT) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
February 26, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
February 23, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
February 17, 2026
Management to host conference call on Thursday, February 26, 2026, at 8:00 am EST
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
February 05, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharma Shows Sales Strength, Targets 2026 Profitability
↗
January 08, 2026
Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q4 sales of $57-$58 million, updated FY2025 revenue guidance to $174.5-$175.5 million.
Via
Benzinga
Get insights into the top gainers and losers of Thursday's pre-market session.
↗
January 08, 2026
Via
Chartmill
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
January 07, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Stay updated with the stocks that are on the move in today's after-hours session.
↗
January 07, 2026
Via
Chartmill
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 07, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
January 07, 2026
From
Phathom Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
